SMO and basal cell carcinoma: All clinically approved Hh pathway inhibitors to date (vismodegib, sonidegib, and glasdegib) are inhibitors of the G protein-like coupled receptor Smoothened (Smo), so-called Smo antagonists, and used primarily in the treatment of basal cell carcinoma and acute myeloid leukemia [86].